Where does parkinson disease pathology begin in the brain?
- PMID: 12030260
- DOI: 10.1093/jnen/61.5.413
Where does parkinson disease pathology begin in the brain?
Abstract
The substantia nigra is not the induction site in the brain of the neurodegenerative process underlying Parkinson disease (PD). Instead, the results of this semi-quantitative study of 30 autopsy cases with incidental Lewy body pathology indicate that PD in the brain commences with the formation of the very first immunoreactive Lewy neurites and Lewy bodies in non-catecholaminergic neurons of the dorsal glossopharyngeus-vagus complex, in projection neurons of the intermediate reticular zone, and in specific nerve cell types of the gain setting system (coeruleus-subcoeruleus complex, caudal raphe nuclei, gigantocellular reticular nucleus), olfactory bulb, olfactory tract, and/or anterior olfactory nucleus in the absence of nigral involvement. The topographical parcellation of the nuclear grays described here is based upon known architectonic analyses of the human brainstem and takes into consideration the pigmentation properties of a few highly susceptible nerve cell types involved in PD. In this sample and in all 58 age- and gender-matched controls, Lewy bodies and Lewy neurites do not occur in any of the known prosencephalic predilection sites (i.e. hippocampal formation, temporal mesocortex, proneocortical cingulate areas, amygdala, basal nucleus of Meynert, interstitial nucleus of the diagonal band of Broca, hypothalamic tuberomamillary nucleus).
Comment in
-
Controversies over the staging of alpha-synuclein pathology in Parkinson's disease.Acta Neuropathol. 2008 Jul;116(1):125-8; author reply 129-31. doi: 10.1007/s00401-008-0381-3. Epub 2008 Apr 30. Acta Neuropathol. 2008. PMID: 18446352 No abstract available.
Similar articles
-
alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei.Acta Neuropathol. 2001 Mar;101(3):195-201. doi: 10.1007/s004010000247. Acta Neuropathol. 2001. PMID: 11307617
-
Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system.Acta Neuropathol. 2000 May;99(5):489-95. doi: 10.1007/s004010051150. Acta Neuropathol. 2000. PMID: 10805091
-
Olfactory pathogenesis of idiopathic Parkinson disease revisited.Mov Disord. 2008 Jun 15;23(8):1076-84. doi: 10.1002/mds.22066. Mov Disord. 2008. PMID: 18442121
-
[Lewy bodies, a misleading marker for Parkinson's disease?].Bull Acad Natl Med. 2003;187(2):277-92; discussion 292-3. Bull Acad Natl Med. 2003. PMID: 14556441 Review. French.
-
[Postmortal diagnosis of Parkinson's disease].Pathologe. 2005 May;26(3):214-20. doi: 10.1007/s00292-004-0722-5. Pathologe. 2005. PMID: 15538572 Review. German.
Cited by
-
Olfactory dysfunction in Parkinson disease.Nat Rev Neurol. 2012 May 15;8(6):329-39. doi: 10.1038/nrneurol.2012.80. Nat Rev Neurol. 2012. PMID: 22584158 Review.
-
Cortical thinning is associated with disease stages and dementia in Parkinson's disease.J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):875-81. doi: 10.1136/jnnp-2012-304126. Epub 2013 Mar 5. J Neurol Neurosurg Psychiatry. 2013. PMID: 23463873 Free PMC article.
-
Gut dysfunction in Parkinson's disease.World J Gastroenterol. 2016 Jul 7;22(25):5742-52. doi: 10.3748/wjg.v22.i25.5742. World J Gastroenterol. 2016. PMID: 27433087 Free PMC article. Review.
-
Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.J Neurol. 2007 Aug;254(8):1037-43. doi: 10.1007/s00415-006-0483-6. Epub 2007 Mar 12. J Neurol. 2007. PMID: 17351722
-
Present and future drug treatment for Parkinson's disease.J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1472-8. doi: 10.1136/jnnp.2004.035980. J Neurol Neurosurg Psychiatry. 2005. PMID: 16227533 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical